The Regents of the University of Minnesota ("Minnesota") appealed from a final decision of the U.S. PTO Patent Trial and Appeal Board ("the Board") holding that the claims of U.S. Patent.
Federal Circuit ruled for Regents Univ of Minnesota v. Gilead Sciences PTAB inter partes review IPR decision finding patent claim drug sofosbuvir not supported by written description in patent application, consistent with Federal Circuits comply Section 112 disclosure reqs
Last month the Federal Circuit affirmed a PTAB inter partes review (IPR) decision finding that the University of Minnesota’s patent claim directed to the anti-cancer drug sofosbuvir was.
Federal Circuit affirmed a Patent Trial Appeal Board decision that there was insufficient written description in the asserted priority applications to support a genus claim because of a lack of ipsis verbis disclosure and insufficient blaze marks.
On March 6, in Regents of the University of Minnesota v. Gilead Sciences, Inc., the Federal Circuit affirmed a decision by the Patent Trial and Appeal Board (PTAB) in an inter partes.